The Association between Mutations Detected in Tissue and Plasma from Patients with Colorectal Adenoma and Adenocarcinoma


Most colorectal cancers evolve through an adenoma-carcinoma sequence with mutations in the KRAS/BRAF pathway as an early event. Mutation analyses are usually performed on tissue samples, but during the last couple of years the same analysis in blood has been facilitated. Our aim was to investigate the correlation between BRAF/KRAS mutations in tissue and plasma from colorectal adenomas and adenocarcinomas. Out of 22 patients with adenomas 10 had a mutation in the tissue, but no mutations were detected in the plasma. In 10 of 26 adenocarcinomas a mutation was found in the tumor and in four of these, the mutation was also detected in the plasma. Our results confirm previous findings that mutated DNA in plasma can be detected in approximately 50% of non-metastasized adenocarcinomas. The difference between adenomas and adenocarcinomas suggests that appearance of mutated DNA in plasma associates with invasion.

Share and Cite:

Larsen, C. , Lindebjerg, J. , Andersen, R. , Pallisgaard, N. , Holck, S. , Jakobsen, A. and Nielsen, H. (2014) The Association between Mutations Detected in Tissue and Plasma from Patients with Colorectal Adenoma and Adenocarcinoma. Journal of Cancer Therapy, 5, 1399-1401. doi: 10.4236/jct.2014.514141.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Fearon, E.R. and Vogelstein, B. (1990) A Genetic Model for Colorectal Tumorigenesis. Cell, 61, 759-767.
[2] Rey, J.W., Kiesslich, R. and Hoffman, A. (2014) New Aspects of Modern Endoscopy. World Journal of Gastrointestinal Endoscopy, 6, 334-344.
[3] Taly, V., Pekin, D., El Abed, A. and Laurent-Puig, P. (2012) Detecting Biomarkers with Microdroplet Technology. Trends in Molecular Medicine, 18, 405-416.
[4] Peyssonnaux, C. and Eychène, A. (2001) The Raf/MEK/ERK Pathway: New Concepts of Activation. Biology of the Cell, 93, 53-62.
[5] Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., et al. (1988) Genetic Alterations during Colorectal-Tumor Development. New England Journal of Medicine, 319, 525-532.
[6] Andersen, R.F., et al. (2015) Improved Sensitivity of Circulating Tumor DNA Measurement Using Short PCR Amplicons. Clinica Chimica Acta, 439, 97-101.
[7] Velho, S., Moutinho, C., Cirnes, L., Albuquerque, C., Hamelin, R., Schmitt, F., et al. (2008) BRAF, KRAS and PIK3CA Mutations in Colorectal Serrated Polyps and Cancer: Primary or Secondary Genetic Events in Colorectal Carcinogenesis? BMC Cancer, 8, 255.
[8] Wynter, C.V.A., Walsh, M.D., Higuchi, T., Leggett, B.A., Young, J. and Jass, J.R. (2004) Methylation Patterns Define Two Types of Hyperplastic Polyp Associated with Colorectal Cancer. Gut, 53, 573-580.
[9] O’Brien, M.J., Yang, S., Mack, C., Xu, H., Huang, C.S., Mulcahy, E., et al. (2006) Comparison of Microsatellite Instability, CpG Island Methylation Phenotype, BRAF and KRAS Status in Serrated Polyps and Traditional Adenomas Indicates Separate Pathways to Distinct Colorectal Carcinoma End Points. American Journal of Surgical Pathology, 30, 1491-1501.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.